Brief: Abbisko Cayman Enters Exclusive Out-License Agreement With Shanghai Allist Pharmaceuticals
01/03/2023 13:56
March 1 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* ENTERED EXCLUSIVE OUT-LICENSE AGREEMENT WITH SHANGHAI
ALLIST
PHARMACEUTICALS CO., LTD.
* AGREEMENT FOR RESEARCH, DEVELOPMENT, MANUFACTURE, USE, AND
SALES
OF (EGFR-TKI) ABK3376 IN CHINA
Further company coverage: 2256.HK
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration